Skip to content

KRYS

Krystal Biotech, Inc.

NASDAQ · USHealthcareBiotechnology
$339.22-4.41%

Price as of Jul 20, 2026

KRYS news

Krystal Biotech, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella’s Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company’s QTORIN™ programs targeting serious

    Globe Newswire ·